Company History
- CTI Molecular Imaging is committed to the success of PET and, today employs over 700 people. Our founders and directors are recognized leaders in the development of PET technology.
- Since 1983, the Company has been at the forefront of technological innovation involving PET Scanners, with its introduction of the first commercial high-resolution PET scanner. CTI remains responsible for the development of many of the major commercial innovations in PET. In 1992, CTI developed the first whole body imaging capability, and, in 1998, CTI invented the combined PET/CT scanner and demonstrated the first clinical image using this scanner. Today, CTI continues to develop PET products and services that lead to earlier, more accurate diagnosis and improve therapy management.
- The Company's goal is to expand and integrate PET into standard clinical practice by delivering innovative solutions that support the adoption of PET in clinical care. CTI has been an active leader and participant in successfully educating Medicare about the benefits of PET. Through The Academy of Molecular Imaging and other associations, we have been successful in increasing the awareness of PET's benefits to patients, physicians and members of the payor community and increasing the number of PET applications for which reimbursement is available.
- In July, 2001, the Centers for Medicare and Medicaid Services (CMS), expanded its policy to cover PET scanning in six oncology, two cardiac, and one neurological application. Most recently, in February 2002, breast cancer staging and restaging and monitoring response to therapy have been approved by Medicare for reimbusement.
